Haermonics

Haermonics is a clinical-stage medtech company based in the Netherlands, focused on innovative solutions to prevent blood-related complications after open-heart surgery. Founded by Dr. David Koolbergen, a prominent heart surgeon, the company has developed the Haermonics Laebroides®, a breakthrough drainage and flushing system. This system employs continuous postoperative pericardial flushing (CPPF) to remove residual blood and clots from the pericardial cavity, significantly reducing the risk of complications such as postoperative bleeding and cardiac tamponades. The Haermonics Laebroides® replaces outdated drainage systems, providing real-time data on a patient’s postoperative hemostatic status. This innovation has shown promising results in clinical trials, reporting zero unnecessary reoperations among 160 patients. Haermonics aims to enhance patient safety and quality of care in cardiac surgery, serving cardiac surgeons, hospitals, and healthcare providers. With a dedicated team of medical, engineering, and regulatory experts, Haermonics is committed to bringing its life-saving technology to market.

• Employees 21
• Founded 2015